Effect of G protein-coupled receptor kinase 2 on the sensitivity of M4 muscarinic acetylcholine receptors to agonist-induced internalization and desensitization in NG108-15 cells.
NG108-15 cells express predominantly the M4 subtype of the muscarinic receptor for acetylcholine. Stimulation of these receptors by the agonist carbachol causes an inhibition of cellular adenylyl cyclase and a consequent fall in the intracellular cyclic AMP concentration. Pretreatment of the cells with carbachol caused both internalization and desensitization of the M4 receptor. Overexpression of G protein-coupled receptor kinase (GRK) 2 caused an increase in the rate constant for receptor endocytosis (from 0.06 to 0.18 min(-1)) and a decrease in the EC50 for carbachol stimulation of internalization (from 15 to 3 microM). Overexpression of a dominant negative form of GRK2 had more modest effects, reducing the rate constant for endocytosis (from 0.11 to 0.07 min(-1)) and increasing the EC50 for carbachol stimulation of internalization (from 8 to 17 microM). Neither GRK2 nor dominant negative GRK2 overexpression had any effect on the rate constant for receptor recycling following agonist removal. The time course and extent of receptor desensitization in control cells were identical to the corresponding values for receptor internalization, and the rate and extent of desensitization were again increased by GRK2 overexpression. Exposure of the cells to hyperosmolar sucrose (0.6 M) almost completely blocked agonist-induced receptor internalization in both control and GRK2-overexpressing cells. Sucrose treatment also blocked agonist-induced desensitization. We conclude that the internalization and desensitization of the M4 muscarinic receptor in NG108-15 cells can be modulated in response to changes in GRK2 activity and also that internalization plays a key role in desensitization.
Holroyd
E W
EW
Department of Pharmacology, University of Cambridge, England.
Szekeres
P G
PG
Whittaker
R D
RD
Kelly
E
E
Edwardson
J M
JM
D000067956:Adenylyl Cyclase Inhibitors; D000465:Algorithms; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D002417:Cattle; D002460:Cell Line; D017868:Cyclic AMP-Dependent Protein Kinases / Q000096:biosynthesis / Q000378:metabolism*; D004705:Endocytosis / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006982:Hypertonic Solutions; D008954:Models, Biological; D018721:Muscarinic Agonists / Q000494:pharmacology*; D011869:Radioligand Assay; D043588:Receptor, Muscarinic M4; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000378:metabolism*; D013395:Sucrose / Q000494:pharmacology; D051552:beta-Adrenergic Receptor Kinases
D000067956:Adenylyl Cyclase Inhibitors; D004791:Enzyme Inhibitors; D006982:Hypertonic Solutions; D018721:Muscarinic Agonists; D043588:Receptor, Muscarinic M4; D011976:Receptors, Muscarinic; D013395:Sucrose; D002217:Carbachol; D017868:Cyclic AMP-Dependent Protein Kinases; D051552:beta-Adrenergic Receptor Kinases